arrow
J

Janbernd Kirschner

University of Freiburg
H指数:64
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

德国、奥地利和瑞士关于使用onasemnogene abeparvovec进行脊髓性肌萎缩基因治疗的德尔菲共识——第二部分——基于专家的建议:副作用监测和管理

2026-08-270
PRE
Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry
Brain
IF11.7
2025-12-230
OAAI
Economic evaluation of next-generation sequencing technologies in paediatric patient groups with confirmed or possible rare diseases: A systematic literature review

下一代测序技术在确诊或疑似患有罕见疾病的儿科患者群体中的经济评估:一项系统文献综述

2025-12-020
OAAI
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland—part I—systematic literature review and existing evidence

德国、奥地利和瑞士关于Onasemnogene Abeparvovec治疗脊髓性肌萎缩基因疗法的德尔菲共识——第一部分——系统文献综述与现有证据

2025-11-240
OA
Respiratory function in 192 adult patients with spinal muscular atrophy (SMA) treated with nusinersen – a multicenter observational study

192例接受nusinersen治疗的脊髓性肌萎缩症(SMA)成年患者的呼吸功能——一项多中心观察性研究

2025-09-290
OA
Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study

5q相关脊髓性肌萎缩症的表型家族内变异性:一项系统性多中心同胞研究

2025-09-120
PRE
TREAT: systematic and inclusive selection process of genes for genomic newborn screening as part of the Screen4Care project

TREAT:Screen4Care项目框架下的基因组新生儿筛查基因的系统性及包容性选择流程

2025-05-150
OA
Characterization of severe COL6-related dystrophy due to the recurrent variant COL6A1 c.930+189C>T

COL6相关严重型肌营养不良的表征:由复发性变异COL6A1 c.930+189C>T引起

Brain
IF11.7
2025-04-030
OA
In response to Gulcin Akinci's and Haluk Topaloglu's letter regarding our article Predictors of loss of ambulation in Duchenne muscular dystrophy: A systematic review and meta-analysis

针对Gulcin Akinci和Haluk Topaloglu关于我们文章《Duchenne肌营养不良症患者行走能力丧失的预测因素:一项系统评价和Meta分析》的信函

2025-02-270
PRE
Efficacy fi cacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study
2024-12-010
OA
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial
2024-12-010
PRE
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy
2024-06-0112
PRE
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam

Chiriboga, C.A.; Bruno, C.; Duong, T.; Fischer, D.; Mercuri, E.; Kirschner, J.; Kostera-Pruszczyk, A.; Jaber, B.; Ksenija, G.; Heidemarie, K.; 等. JEWELFISH:一项开放标签研究中接受Risdiplam治疗的非初治型脊髓性肌萎缩症患者的24个月结果。J. Neurol. 2024, 271, 4871–4884. [Google Scholar] [CrossRef]

2024-05-110
OAAI
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
2024-04-019
OA